Activist Altai Capital Launches Proxy Contest, Demands Strategic Review and Board Changes

summarizeSummary

Altai Capital Management, a 5.2% shareholder, has launched a proxy contest to elect two new directors and is demanding a strategic review, including a potential sale of OraSure Technologies, citing chronic underperformance and misaligned executive compensation.

check_boxKey Events

• Proxy Contest Launched

  Altai Capital Management, holding a 5.2% stake, has formally launched a proxy contest to elect two new directors, Rishi Bajaj and John Bertrand, to OraSure's Board.

• Demand for Strategic Review

  The activist is advocating for a comprehensive strategic review, including the potential sale of the entire business, which they estimate could yield a 42% to 107% premium over the current stock price.

• Criticism of Underperformance & Governance

  Altai criticizes OraSure's chronic stock underperformance, speculative acquisitions (Sapphiros, Sherlock Biosciences), the Board's low share ownership, and the CEO's compensation structure, which they argue is not aligned with shareholder interests.

• Minor Share Sale Reported

  Altai Capital Management reported a sale of 127,000 shares on March 13, 2026, for portfolio management purposes, explicitly stating it does not reflect their views on the Issuer's future prospects.

auto_awesomeAnalysis

This Schedule 13D/A details Altai Capital Management's aggressive activist campaign against OraSure Technologies. The filing outlines a comprehensive case for change, highlighting the company's significant underperformance, the board's lack of "skin in the game," and a CEO compensation structure not tied to shareholder returns. Altai is pushing for a strategic review that could lead to a sale of the company, estimating a potential premium of 42% to 107% over the current share price. This represents a critical challenge to the current management and board, with the potential to unlock substantial shareholder value if the activist's nominees are elected and their proposals are adopted. Investors should closely monitor the proxy contest and the company's response.